Get the Stockscreener App
3.88
9.35%
-0.40
Zura Bio Ltd stock is traded at $3.88, with a volume of 4.88M.
It is down -9.35% in the last 24 hours and down -15.84% over the past month.
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.
See More
Previous Close:
$4.28
Open:
$4.3
24h Volume:
4.88M
Relative Volume:
0.93
Market Cap:
$371.82M
Revenue:
Net Income/Loss:
$-75.43M
P/E Ratio:
-3.1801
EPS:
-1.2201
Net Cash Flow:
$-72.75M
1W Performance:
-3.00%
1M Performance:
-15.84%
6M Performance:
-32.05%
1Y Performance:
+13.12%
1-Day Range:
$3.86
$4.35
1-Week Range:
$3.85
$4.78
52-Week Range:
$3.15
$7.44
Zura Bio Ltd Stock (ZURA) Company Profile
Name
Zura Bio Ltd
Sector
Industry
Phone
858-247-0520
Address
4225 EXECUTIVE SQUARE, LA JOLLA
Compare ZURA vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZURA
Zura Bio Ltd
|
3.88 | 371.82M | 0 | -75.43M | -72.75M | -1.2201 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Zura Bio Ltd Stock (ZURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-08-26 | Initiated | William Blair | Outperform |
| Feb-09-26 | Initiated | Wedbush | Outperform |
| Nov-04-24 | Initiated | Leerink Partners | Outperform |
| Sep-05-24 | Initiated | H.C. Wainwright | Neutral |
| May-03-24 | Initiated | Piper Sandler | Overweight |
| Oct-10-23 | Initiated | Ladenburg Thalmann | Buy |
| Aug-25-23 | Initiated | Oppenheimer | Outperform |
| Jun-22-23 | Initiated | Guggenheim | Buy |
| Jun-14-23 | Initiated | Chardan Capital Markets | Buy |
| May-24-23 | Initiated | Raymond James | Strong Buy |
View All
Zura Bio Ltd Stock (ZURA) Latest News
Zura Bio (ZURA) Hits Enrollment Milestones As Losses Widen Sharply - Yahoo Finance
Zura Bio at 12th annual cantor fitzgerald global healthcare conference: data ahead - Investing.com Nigeria
Zura Bio at 12th annual cantor fitzgerald global healthcare conference: data ahead By Investing.com - Investing.com South Africa
Zura Bio at 12th annual cantor fitzgerald global healthcare conference: data ahead - Investing.com Canada
Zura Bio at 12th annual cantor fitzgerald global healthcare conference: data ahead - Investing.com India
CABA Stock Price and Chart — NASDAQ:CABA - TradingView
Zura Bio to Participate in the Cantor Global Healthcare Conference - Yahoo Finance
This Zura Bio Insider Increased Their Holding In The Last Year - simplywall.st
Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Zura Bio (NASDAQ: ZURA) director plans 50,000-share sale after prior trades - Stock Titan
Zura Bio (NASDAQ: ZURA) affiliate plans stock sale via option exercise - Stock Titan
Zura Bio Releases Updated Corporate Presentation in Latest SEC Filing - Kalkine Media
Zura Bio updates corporate presentation; HS Phase 2 topline Q4 2026, SSc readout H1 2027, cash runway through 2028 - TradingView
Zura Bio Limited (NASDAQ:ZURA) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
ZURA (ZURA) insider Someit Sidhu plans 40,000-share sale after option exercise - Stock Titan
Zura Bio Ltd SEC Filing (Aug 13, 2026) - Stock Titan
Wedbush Maintains Zura Bio(ZURA.US) With Buy Rating, Raises Target Price to $22 - Moomoo
Zura Bio Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
Guggenheim raises Zura Bio stock price target on new drug indication - Investing.com
Guggenheim raises Zura Bio stock price target on new drug indication - Investing.com India
Guggenheim raises Zura Bio stock price target on new drug indication - Investing.com
Zura Bio Submits Q2 2026 SEC Report Highlighting Financial and Operational Status - Kalkine Media
Zura Bio Q2 Results: EPS Misses Estimate as Losses Widen 23.53% YoY - scanx.trade
Zura Bio Limited Reports Q2 2026 Financial Results and Updates Investor Presentation in 8-K Filing - Kalkine Media
Form 8K Zura Bio Limited For: 11 August By Investing.com - Investing.com Nigeria
Form 8K Zura Bio Limited For: 11 August By Investing.com - Investing.com South Africa
Form 8K Zura Bio Limited For: 11 August By Investing.com - Investing.com Canada
Zura Bio Ltd 2Q 2026: Net loss $(26.3)M, EPS $(0.21) — 10-Q Summary - TradingView
Financial update and recent changes drive Zura Bio performance - Traders Union
Zura Bio Completes Enrollment in 247-Participant Hidradenitis Study - Stock Titan
Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates - Yahoo Finance
Zura Bio Ltd expected to post a loss of 20 cents a shareEarnings Preview - TradingView
Zura Bio Ltd (ZURA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Zura Bio (ZURA) Projected to Announce Earnings on Thursday - MarketBeat
1,179,715 Shares in Zura Bio Limited $ZURA Purchased by EcoR1 Capital LLC - MarketBeat
Zura Bio Ltd (ZURA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Zura Bio Ltd (ZURA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Zura Bio Ltd (ZURA) Cash Flow - TradingKey
Zura Bio Ltd (ZURA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Zura Bio Ltd (ZURA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ZURA|Zura Bio Ltd|Price:5.230|Chg%:-0.060 - TradingKey
Zura Bio Ltd (ZURA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Zura Bio Ltd (ZURA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ZURA|Zura Bio Ltd|Price:5.240|Chg%:-0.140 - TradingKey
TradingKey - TradingKey
Marlyn Teresa Mathew Net Worth (2026) - GuruFocus
William Blair Starts Zura Bio (ZURA) at Outperform - Yahoo Finance
ZURA Initiated Coverage by William Blair -- Rating Set to Outper - GuruFocus
Zura Bio Ltd Stock (ZURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Zura Bio Ltd Stock (ZURA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SOMEIT SIDHU | Director |
Aug 17 '26 |
Proposed Sale |
5.61 |
27,000 |
151,343 |
0 |
| SOMEIT SIDHU | Director |
Aug 14 '26 |
Proposed Sale |
5.51 |
40,000 |
220,540 |
0 |
| SOMEIT SIDHU | Director |
Aug 13 '26 |
Proposed Sale |
5.63 |
51,000 |
287,043 |
0 |
| AI Biotechnology LLC | 10% Owner |
Feb 26 '26 |
Buy |
6.25 |
2,000,000 |
12,500,000 |
6,552,725 |
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):